MedicarePartD.guide

A non-government resource built from CMS public data

HIV treatment and prevention on every 2026 Oregon Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Oregon cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
HIV treatment and prevention by 2026 Oregon Part D plan
DrugWellcare Classic$0.00/moS4802-020Wellcare Value Script$0.00/moS4802-135HealthSpring Assurance Rx$0.00/moS5617-148Humana Basic Rx Plan$0.00/moS5884-113Humana Value Rx Plan$22.10/moS5884-209AARP Medicare Rx Saver from UHC$38.40/moS5921-374HealthSpring Extra Rx$50.00/moS5617-380SilverScript Choice$85.90/moS5601-060Humana Premier Rx Plan$108.60/moS5884-176AARP Medicare Rx Preferred from UHC$110.00/moS5921-411
Biktarvybictegravir/emtricitabine/tenofovir alafenamideTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%Tier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Dovatodolutegravir and lamivudineTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%Tier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Triumeqabacavir/dolutegravir/lamivudineTier 428%Tier 440%Tier 430%QL 300/30dTier 433%QL 180/30dTier 433%QL 180/30dTier 436%QL 180/30dTier 430%QL 300/30dTier 433%Tier 450%QL 180/30dTier 437%QL 180/30d
Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%Tier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Odefseyemtricitabine/rilpivirine/tenofovir alafenamideTier 525%Tier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%Tier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Julucadolutegravir and rilpivirineTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%Tier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Descovyemtricitabine and tenofovir alafenamideTier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Truvadaemtricitabine and tenofovir disoproxilNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
emtricitabine-tenofovirgeneric TruvadaTier 428%QL 30/30dTier 440%QL 30/30dTier 430%QL 30/30dTier 433%QL 30/30dTier 433%QL 30/30dTier 436%QL 30/30dTier 430%QL 30/30dTier 433%QL 30/30dTier 450%QL 30/30dTier 437%QL 30/30d
TivicaydolutegravirTier 525%Tier 525%Tier 430%QL 180/30dTier 525%QL 60/30dTier 526%QL 60/30dTier 525%QL 60/30dTier 430%QL 180/30dTier 525%Tier 533%QL 60/30dTier 531%QL 60/30d

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.